Atossa Therapeutics Files 8-K for Financial Reporting
Ticker: ATOS · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.18 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, operations
Related Tickers: ATOS
TL;DR
ATOS filed an 8-K on Aug 12, 2025, covering financial results and exhibits. Check it for company health updates.
AI Summary
Atossa Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing details the company's ongoing business activities and financial reporting requirements.
Why It Matters
This filing provides crucial updates on Atossa Therapeutics' financial health and operational status, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- August 12, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Seattle, Washington (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
This 8-K filing pertains to the 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on August 12, 2025.
What is the principal executive office address for Atossa Therapeutics, Inc.?
The principal executive offices are located at 10202 5th Avenue NE, Suite 200, Seattle, Washington 98125.
What is the Commission File Number for Atossa Therapeutics, Inc.?
The Commission File Number is 001-35610.
Has Atossa Therapeutics, Inc. had a former name?
Yes, the former company name was ATOSSA GENETICS INC, with a date of name change on March 25, 2010.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-08-12 08:40:29
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
Filing Documents
- atos-20250812.htm (8-K) — 55KB
- atos-ex99_1.htm (EX-99.1) — 339KB
- img248274862_0.jpg (GRAPHIC) — 5KB
- 0000950170-25-106944.txt ( ) — 531KB
- atos-20250812.xsd (EX-101.SCH) — 28KB
- atos-20250812_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 12, 2025, Atossa Therapeutics, Inc. (the "Company") issued a press release announcing the quarter ended June 30, 2025 financial results and providing a Company update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 9.01 of this report, including Exhibit 99.1 attached hereto, shall not be deemed to be " filed " for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 12, 2025 104 Cover page Interactive Data File (embedded within the Inline XBRL document) * * *
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: August 12, 2025 By: /s/ Heather Rees Heather Rees Chief Financial Officer (Principal Financial and Accounting Officer)